Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 219Neoplasms 177Lung Neoplasms 92Prostatic Neoplasms 89Colorectal Neoplasms 88Carcinoma, Non-Small-Cell Lung 48Stomach Neoplasms 45Motor Activity 45Carcinoma, Hepatocellular 45Pancreatic Neoplasms 40Uterine Cervical Neoplasms 39Anxiety Disorders 39Rectal Neoplasms 34Head and Neck Neoplasms 31Colonic Neoplasms 30Pain 26Depression 26Brain Neoplasms 25Polycystic Ovary Syndrome 24Esophageal Neoplasms 24Disease 23Multiple Myeloma 22Hematologic Neoplasms 22Endometrial Neoplasms 22Ovarian Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Urinary Bladder Neoplasms 18Pain, Postoperative 18Glioblastoma 18Liver Neoplasms 17

Interventions

apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Not yet recruiting × Ovarian Cancer Recurrent × Clear all
NCT06102707 2023-10-26

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Qilu Hospital of Shandong University

Phase NA Not yet recruiting
50 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡